Tscan Therapeutics Inc
TCRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.17M
Close$
$-1.58
248.9% downside
Current Fair Value
248.9% downsideOvervalued by 248.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.17 Million |
|---|---|
| Enterprise Value | $-7,368,287.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 1.03 |
| Outstanding Shares | 129,913,376 |
Return
| Return on Equity | -128.25% |
|---|---|
| Return on Assets | -61.54% |
| Return on Invested Capital | -69.05% |
Valuation & Multiples
| P/E Ratio | -1.01 |
|---|---|
| PEG | 6.31 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.11 |
| Enterprise Value to EBIT | 0.06 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -8.35 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$2.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.99%▲ 1.35% |
|---|---|
| Total Invested | $32.78M▲ 6.81% |
| Investors Holding | 58▼ 2.00% |
ESG Score
No data
About Tscan Therapeutics Inc
61 employees